Synergy CHC Corp. (SNYRQ)
As-reported financials and SEC filings for Synergy CHC Corp. The latest annual period is FY2025. The latest reported quarter is Q1 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Synergy CHC Corp.
Synergy CHC Corp. produces and sells nutritional supplements. The company offers a range of health and wellness products primarily to consumers seeking dietary supplements. It operates in a competitive industry and relies on relationships with a limited number of large customers.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Synergy CHC
- Revenue fell 12.8% to $30M in FY2025, after a 18.6% decline the year before.
- Operating margin is -27.8% in FY2025, -13.3 pp against -14.5% in FY2018.
- Most recent quarter Q1 FY2026: revenue $5M, down 32.8% from Q1 FY2025.
- Net income turned to a $12M loss in FY2025, from a $2M profit in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Synergy CHC’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Synergy CHC’s net margin of -40.6% ranks in the 14th percentile of the 417 Healthcare companies reporting it.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice.
Institutional ownership
Held by 1 quant / multi-strat book among the superinvestors we track; no conviction manager currently reports a position.
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| Citadel Advisorsquant | Q2 2026 | $2,164 | 10.9K | New |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | |
|---|---|---|---|---|---|
| Revenue | $30.4M | $34.8M | $42.8M | $29.4M | $33.8M |
| Gross profit | $20.3M | $23.6M | $32.1M | $20.2M | $22.8M |
| Operating income | $-8.5M | $5.8M | $10.8M | $-8.0M | $-4.9M |
| Net income | $-12.3M | $2.1M | $6.3M | $-9.2M | $-6.2M |
| Diluted EPS | $-1.27 | $0.28 | $0.86 | $-1.20 | $-0.84 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | |
|---|---|---|---|---|---|
| Cash and equivalents | $2.6M | $687,920 | $632,534 | $1.2M | $459,736 |
| Current assets | $10.0M | $16.1M | $11.8M | $5.0M | $8.9M |
| Total assets | $10.2M | $16.3M | $12.2M | $5.2M | $20.0M |
| Current liabilities | $8.2M | $17.2M | $14.0M | $10.1M | $10.4M |
| Long-term debt | $25.1M | $7.5M | $13.1M | — | — |
| Total liabilities | $33.3M | $33.0M | $39.5M | $10.4M | $16.0M |
| Total equity | $-23.1M | $-16.6M | $-27.3M | $-5.2M | $4.0M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | |
|---|---|---|---|---|---|
| Operating cash flow | $-2.6M | $-4.8M | $421,729 | $2.9M | $1.3M |
| Capital expenditure | — | — | — | — | $129,087 |
| Free cash flow | — | — | — | — | $1.2M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2026 | $5.5M | -32.8% | $-2.6M | $-0.23 |
| Q4 FY2025 | $6.1M | 11.6% | $-14.8M | $-1.32 |
| Q3 FY2025 | $8.0M | 12.4% | $125,327 | $0.01 |
| Q2 FY2025 | $8.1M | 1.4% | $1.5M | $0.17 |
| Q1 FY2025 | $8.2M | -13.2% | $876,264 | $0.10 |
| Q4 FY2024 | $5.4M | -58.9% | $105,667 | $0.01 |
| Q3 FY2024 | $7.1M | -34.1% | $783,593 | $0.11 |
| Q2 FY2024 | $8.0M | — | $655,186 | $0.09 |
Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth quarter we calculated: the full year minus the first nine months.
Company facts
Selected SEC filings
Largest Healthcare peers
Monitor SNYRQ
Get an alert when Synergy CHC files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor SNYRQ freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.